More Thai protests on US FTA talks

13 February 2006

Thousands of people have protested at the Thailand-US Free Trade Agreement (FTA) talks in the northern city of Chiang Mai, where negotiators carried out their sixth round of talks since mid-2004, with both sides hopeful of an agreement within the next few months (Marketletter January 16). The protestors claimed the FTA would undermine national sovereignty, result in higher product prices, and cut off access to generic drugs for local patients. US officials insisted that negotiations over patent issues would not result in reduced access to drugs by Thai patients, a key point of contention.

Thai negotiators should consider any US demands regarding intellectual property rights carefully, according to Somkiat Tangkitvanich of the Thailand Development Research Institute, who stated the US typically required trading partners to agree conditions for IP protection, particularly for pharmaceutical patents, that went beyond existing international agreements. For example the US-Chile FTA included a number of restrictions on generic drugs and unlicensed imports, which the USA was likely to also require in a Thai agreement.

Ms Neena Moorjani, a spokeswoman for the US Trade Representative, replied at a press conference by saying: "patent issues related to pharmaceuticals would be discussed, but protesters were misguided in their claims that a deal would result in higher drug prices. The FTA will not increase the price of generic or innovative drugs. Our objective is to promote development of new drugs while ensuring continued access to all medication, so Thai HIV/AIDS and other patients will continue to obtain the newest and most effective drugs."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight